These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 8313400)

  • 1. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
    Lotufo-Neto F; Trivedi M; Thase ME
    Neuropsychopharmacology; 1999 Mar; 20(3):226-47. PubMed ID: 10063483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J; Becker T; Ziegler V; Laux G; Riederer P
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
    Kennedy SH
    J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F; Wolfersdorf M
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brofaromine in endogenous depression.
    Verhoeven WM
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):235-41. PubMed ID: 8208975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
    Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
    J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
    Roth M; Guelfi JD
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():18-24. PubMed ID: 1394027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antidepressive agents in the elderly].
    de Hooge JK
    Tijdschr Gerontol Geriatr; 1990 Dec; 21(6):259-67. PubMed ID: 1980385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
    Celada P; Pérez J; Alvarez E; Artigas F
    J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase inhibitors: reversible and irreversible.
    Rudorfer MV
    Psychopharmacol Bull; 1992; 28(1):45-57. PubMed ID: 1609042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.
    Shulman KI; Fischer HD; Herrmann N; Huo CY; Anderson GM; Rochon PA
    J Clin Psychiatry; 2009 Dec; 70(12):1681-6. PubMed ID: 19852903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of antidepressants: clinical pharmacology and therapy.
    Baldessarini RJ
    J Clin Psychiatry; 1989 Apr; 50(4):117-26. PubMed ID: 2647712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moclobemide for depression.
    Drug Ther Bull; 1994 Jan; 32(1):6-8. PubMed ID: 7635005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.